PDCD1 and acral lentiginous melanoma: Nakamura et al., retrospectively examined 193 advanced-stage Japanese ALM patients treated with anti-PD-1 antibodies and, surprisingly, found that anti-PD-1 antibodies with lower response rates were observed in patients with nail apparatus melanoma than those with palm and sole melanoma.